« News

Helsinn Group and MEI Pharma Enter Strategic Agreement for the Development and Commercialization of Pracinostat for the Treatment of Acute Myeloid Leukemia and Other Hematologic Diseases

MEI Pharma to receive $20 million in near-term cash payments, plus up to $444 million in potential milestone payments as well as royalties on future sales.

Agreement enables Helsinn to expand into oncology therapeutics with new Phase III-ready asset

MEI Pharma to host conference call today at 9:00 am Eastern time

Click the following link for the press release: